Furthermore, previous studies reported similar results that TMB is higher in NSCLC patients with HER2 amplification than those with HER2 mutations in mixed cohorts consisting of early and advanced disease, which is thought to be associated with the higher prevalence of male smokers in HER2-amplified group (25, 26). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.